The Structural Repricing of Healthcare AI

The rapid decay of foundation model inference costs, paired with the proliferation of high-performing open-source architectures, has initiated a deflationary wave across the software landscape. In healthcare technology, where software historically commanded premium valuation multiples due to high switching costs and regulatory moats, this shift has exposed a structural divide. 

The market no longer awards a generalised "AI premium" to applications that merely expose a thin user interface over third-party Large Language Model (LLM) Application Programming Interfaces (APIs). Instead, institutional buyers, corporate acquirers, and growth equity investors are conducting rigorous AI defensibility analyses during deal diligence, sharply distinguishing thin AI wrappers from deeply integrated, defensible health AI platforms.
  
This repricing has created a stark valuation bifurcation. Thin AI applications and point solutions built without proprietary data or deep workflow integration have experienced dramatic multiple compression, falling from high-growth software multiples to distressed or asset-sale valuation levels ranging from 1x to 3.5x Annual Recurring Revenue (ARR). Conversely, health AI platforms that demonstrate high net revenue retention (NRR > 120%), deep electronic health record (EHR) write-back capabilities, proprietary clinical datasets, and regulatory clearances continue to clear institutional funding rounds and M&A transactions at 8x to 20x+ revenue multiples, with core infrastructure and category-defining platforms commanding even higher premiums.

Public software valuation medians have contracted significantly, with public SaaS multiples hovering around 3.4x to 4.8x ARR due to investor anxieties surrounding AI agent substitution for traditional per-seat licensing. In private healthcare M&A, buyers are penalizing companies that rely heavily on manual professional services or generic model calls, while rewarding assets that achieve capital efficiency and satisfy the Rule of 40 (Growth % + EBITDA Margin % > 40). 
  
To survive this deflationary cycle, healthcare AI enterprises must objectively evaluate their technical defensibility and execute strategic repositioning moves to shift from fragile systems of engagement to entrenched systems of record.

Click here to read the full report https://www.healthcare.digital/single-post/the-ai-deflation-wave-platform-versus-wrapper-valuation-dynamics-in-healthcare-ai